Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.
Torsades de pointes (TdP) has not been previously reported with loratadine. A 73-year old woman on chronic treatment with amiodarone for atrial fibrillation received loratadine and presented with syncope and multiple episodes of TdP. We suggest that QT interval should be monitored whenever loratadine is co-administered with drugs that may potentially prolong QT.
Atar
Shaul
S
Department of Cardiology, Ha'Emek Medical Center, Afula 18101, Israel. atar_sh@clalit.org.il
Freedberg
Nahum A
NA
Antonelli
Dante
D
Rosenfeld
Tiberio
T
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D018926:Anti-Allergic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D017336:Loratadine / Q000009:adverse effects* / Q000627:therapeutic use; D016171:Torsades de Pointes / Q000139:chemically induced*
D018926:Anti-Allergic Agents; D000889:Anti-Arrhythmia Agents; D017336:Loratadine; D000638:Amiodarone